HOPKINTON, Mass. and BRANFORD, Conn., March 10, 2011
/PRNewswire/ — Caliper Life Sciences, Inc. (Nasdaq:
CALP) and HistoRx, Inc., today announced a collaboration to
co-develop a new generation of tissue-based imaging and analysis
solutions, based on immuno-fluorescence, that will deliver
accurate, quantitative, and reproducible measurements of proteins
in tissue samples. The collaboration will enable researchers
to leverage the combined imaging and analysis power of Caliper’s
Vectra™, an automated multiplexed tissue imaging platform,
and AQUA® technology, HistoRx’s proprietary image analysis
system, to provide an integrated platform to advance the
identification and validation of new drug targets and improve
assessment of drug response.
“The Vectra system from Caliper represents a significant move
forward for researchers interested in digital pathology with
multispectral, brightfield, and fluorescent capabilities,” said
Bill Sullivan, Senior Vice President of Operations at HistoRx.
“By matching AQUA technology’s intensity-based quantitative
measurement with Caliper’s market leading multispectral imaging
capabilities, users will be afforded a level of quality and
performance that is unparalleled. Caliper is therefore a
natural partner for HistoRx in bringing reproducible and truly
quantitative immunohistochemistry to the anatomic pathology
laboratory.”
“The combination of Caliper and HistoRx technologies enables an
unprecedented level of objective and accurate diagnosis that is
currently lacking, both on the research level as well as the
clinical level,” said Kevin Hrusovsky, President and Chief
Executive Officer of Caliper Life Sciences. “We see an
opportunity to bring a comprehensive solution to the research
market to help expand scientists’ options for capturing key disease
signatures and to aid in the developmen
‘/>”/>
